Merck & Co., Inc. Available-for-sale Securities, Gross Unrealized Loss
Merck & Co., Inc. (MRK) reported Available-for-sale Securities, Gross Unrealized Loss of $8.00 million for the 3-month period ending 2011-03-31, per its 10-Q filed 2011-05-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2011-05-09
- Merck & Co., Inc. available-for-sale securities, gross unrealized loss for the quarter ending 2011-03-31 was $8.00M.
- Merck & Co., Inc. available-for-sale securities, gross unrealized loss for the quarter ending 2010-12-31 was $14.80M.
- Merck & Co., Inc. available-for-sale securities, gross unrealized loss for the quarter ending 2010-09-30 was $6.60M.
- Merck & Co., Inc. available-for-sale securities, gross unrealized loss for fiscal 2009 was $19.00M.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 3 month | Available-for-sale Securities, Gross Unrealized Loss 6 month | Available-for-sale Securities, Gross Unrealized Loss 9 month | Available-for-sale Securities, Gross Unrealized Loss 12 month | Available-for-sale Securities, Gross Unrealized Loss 12 month as first filed |
|---|---|---|---|---|---|
| 2011-03-31 | $8.00M 10-Q · filed 2011-05-09 | $22.80M derived: sum of 2 quarters · filed 2011-05-09 | $29.40M derived: sum of 3 quarters · filed 2011-05-09 | ||
| 2010-12-31 | $14.80M derived: 10-Q 12 month − 10-Q 9 month · filed 2011-05-09 | $21.40M derived: sum of 2 quarters · filed 2011-05-09 | $16.00M 10-Q · filed 2011-05-09 | ||
| 2010-09-30 | $6.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-08 | $1.20M 10-Q · filed 2010-11-08 | |||
| 2010-06-30 | -$5.40M 10-Q · filed 2010-08-06 | ||||
| 2009-12-31 | $19.00M 10-K · filed 2011-02-28 | -$18.90M 10-Q · filed 2010-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |